Background
==========

Mucosal immunity is critical in AIDS virus infection because most transmission is through mucosal surfaces and the GI mucosa is a major reservoir for virus replication. There is window in time in which mucosal T cells could potentially eradicate a nascent local mucosal infection before it disseminates. In most vaccine work, adjuvant-induced innate immunity was of interest only to improve adaptive immunity. Here, in addition to adaptive immunity, we also examine direct adjuvant effects on innate immune protection.

Methods
=======

We compared mucosal vaccine strategies involving synergistic TLR ligands, IL-15, both or neither as adjuvants with peptide-prime/MVA boost intrarectal vaccine, and have searched for possible correlates of protection against mucosal challenge.

Results
=======

Only the group receiving all the adjuvants together with vaccine antigens achieved at least partial protection of rhesus macaques against intrarectal SIVmac251 challenge in 3 of 5 macaques. The optimal combination of several TLR ligands and IL-15 induced not only a more effective adaptive T cell response, but also an innate immune response that directly impacted protection. In the innate response, we found evidence for vaccine-induced long-lasting upregulation of APOBEC3G that provided some protection even in control animals that received only the adjuvants without the vaccine antigens. In the adaptive response, only polyfunctional CD8 T cells correlated with protection, whereas levels of tetramer-positive cells and even effector and central memory T cells surprisingly did not.

Conclusion
==========

Thus, strategic use of combinations of molecular adjuvants can provide better mucosal protection through induction of both innate and adaptive immunity.
